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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S399were younger and had higher levels of hip-related pain and
disability. The LBP group also had a higher number of painful
spinal levels and pelvic pain provocation tests. Results should be
interpreted with caution due to the low sample size. Further
research is warranted to explore the cause and effect relationship
and underlying pain mechanisms associated with co-existing hip
OA and LBP.DSPCC 35 mg TID (n[ 98) DSPCC 35 mg BID (n[ 104) Placebo (n[ 103)
(n[ 96) (n[ 102) (n[ 96)
Subjects with  30% reduction from baseline to week 12 75 (78.1 %) 70 (68.6%) 58 (60.4%)
P value 0.0078 0.2271
Subjects with  50% reduction from baseline to week 12 60 (62.5%) 57 (55.9%) 44 (45.8%)
P value 0.0205 0.1575
P-values are compared with placebo.712
LOWER-DOSE DICLOFENAC CAPSULES DEVELOPED USING
SOLUMATRIX FINE PARTICLE TECHNOLOGY RESULT IN CLINICALLY
MEANINGFUL IMPROVEMENTS IN PAIN IN A PHASE 3 STUDY OF
PATIENTS WITH OSTEOARTHRITIS
C. Young y, D. Parenti y, M. Hochberg z. y Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA; zUniv. of Maryland, Baltimore, MD, USA
Purpose: Osteoarthritis (OA) is characterized by acute and chronic pain
and reduced physical function. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are frequently prescribed for the management of OA pain. As a
class, NSAIDs are associated with dose-related serious gastrointestinal,
cardiovascular, and renal adverse events which has prompted interna-
tional health authorities and the United States Food and Drug Admin-
istration to recommend that NSAIDs be used at the lowest effective dose
for the shortest possible duration. Diclofenac submicron particle con-
taining capsules (DSPCC) consisting of submicron drug particles and a
proprietary combination of excipients were developed using SoluMa-
trix Fine Particle Technology to provide efﬁcacy at lower doses than
commercially available diclofenac drug products and are licensed for
treatment of mild-to-moderate acute pain in adults. As previously
reported, DSPCC 35 mg three times daily (TID) signiﬁcantly reduced the
Western Ontario and McMaster University Osteoarthritis Index
(WOMAC) pain subscale score compared with placebo (P ¼ 0.0024) in a
phase 3 study in adults with OA pain of the hip or knee. Therewas some
evidence of improvement in theWOMAC pain subscale score compared
with placebo for DSPCC 35 mg twice daily (BID), although this did not
achieve statistical signiﬁcance (P ¼ 0.08). We report the results for
measures of clinically meaningful pain relief following treatment with
low-dose DSPCC in the phase 3 study.
Methods: This multicenter, randomized, double-blind, placebo-con-
trolled study enrolled patients 40 years with clinically and radio-
logically conﬁrmed (Kellgren-Lawrence grade II-III) hip or knee OA pain.
Eligible patients were chronic NSAID and/or acetaminophen users with
baseline WOMAC pain subscale scores 40 mm (based on 100-mm
Visual Analog Scale) and a documented OA ﬂare (15-mm increase in
WOMAC pain subscale score from screening). Patients were random-
ized to receive DSPCC 35 mg TID, DSPCC 35 mg BID, or placebo for 12
weeks. Efﬁcacy parameters included responder rates for patients who
achieved a reduction of 10 mm in pain intensity from baseline based
on theWOMAC pain subscale score at week 2, 6, and 12; the proportion
of patients with a reduction (0%-100%) in WOMAC pain subscale score
at week 12 (continuous responder analysis); and the proportion of
patients who discontinued from the study due to lack of efﬁcacy.
Results: Overall, 305 patients were randomized. The mean (SD) age of
patients was 61.6 (8.9) years and 66.6% were female. Both DSPCC 35 mg
TID (86/96, 89.6% [P ¼ 0.007]) and BID (86/102, 84.3% [P ¼ 0.0148])
resulted in signiﬁcantly more patients achieving 10-mm reductions in
the WOMAC pain subscale score from baseline compared with placebo
(67/96, 69.8%) at week 12. Similar effects were noted at week 2 (DSPCC
35 mg TID: 73/94, 77.7% [P ¼ 0.0130]; DSPCC 35 mg BID: 78/100, 78.0%
[P ¼ 0.0098]; placebo: 56/92, 60.9%) and week 6 (DSPCC 35 mg TID: 76/
86, 88.4% [P ¼ 0.0031]; DSPCC 35 mg BID: 76/91, 83.5% [P ¼ 0.0338];
placebo: 61/87, 70.1%). The DSPCC 35 mg TID and BID groups experi-
enced greater reductions in pain intensity compared with placebo.
More than two-thirds of patients in the DSPCC 35 mg TID and BIDgroups achieved a reduction of30% in theWOMAC pain subscale score
from baseline and amajority of patients achieved a reduction of50% at
week 12 based on continuous responder analysis (Table). No patients in
the DSPCC 35 mg TID group and 2 patients (1.9%) in the DSPCC 35 mg
BID group withdrew from the study due to lack of efﬁcacy compared
with 6 patients (5.8%) in the placebo group.Conclusions: Treatment with DSPCC 35 mg TID and BID resulted in
clinically meaningful improvements in pain in this study in patients
with OA of the hip or knee.
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INTRA-ARTICULAR INFILTRATION THERAPY FOR PATIENTS WITH
GLENOHUMERAL OSTEOARTHRITIS. A SYSTEMATIC REVIEW OF THE
LITERATURE.
S. Colen y, P. Geervliet z, D. Haverkamp x, M. van den Bekerom k. yUniv.
Hosp. Leuven, Leuven, Belgium; zGemini Hosp., Dept. of Orthopaedic
Surgery, Den Helder, Netherlands; x Slotervaart Hosp., Dept. of
Orthopaedic Surgery, Amsterdam, Netherlands; kOnze Lieve Vrouwe
Gasthuis, Dept. of Orthopaedic Surgery, Amsterdam, Netherlands
Purpose: Conservative treatments are especially in patients with GH-
OA important, since shoulder arthroplasty has its limitations. In this
systematic review we will evaluate the current evidence regarding the
efﬁcacy of intra-articular inﬁltration treatment options in patients with
glenohumeral osteoarthritis (GH-OA).
Methods: The following databases are searched: Pubmed/Medline,
Cochrane Clinical Trial Register, Embase and the WHO clinical trial
register. All intra-articular injection products used for the treatment of
shoulder OA in humans are included.
Results: A total of 8 studies could be included in this review. Hyaluronic
acid (HA) showed effect sizes of 2.07, 2.02 and 2.11 at 6,12 and 26weeks
follow-up, respectively. Placebo (1.60 , 1.82 and 1.68) also showed stable
effect sizes at the same time points. The efﬁcacy of corticosteroids (CS)
decreased rapidly at follow-up (1.08, 0.43 and 0.19). Although statistical
signiﬁcant, the maximum difference in effect sizes between HA and
placebo was only 0.43 with absolute values between 2.0 and 6.4 on a
100-point VAS for pain.
Conclusion: Intra-articular treatment with HA has a good efﬁcacy at
follow-up compared to baseline. However, the difference in efﬁcacy
between HA and placebo never reaches the minimal clinically impor-
tant difference at any of the follow-up points. We are not able to give
clear recommendations for the use of intra-articular CS injections in
patients with GH-OA. In future research we recommend to focus on
sufﬁciently powered randomized trials to compare the efﬁcacies of HA,
CS, placebo and other intra-articular treatment options in patients with
GH-OA.
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IMPROVEMENT IN CARTILAGE FOLLOWING INTRA-ARTICULAR
INJECTION OF TG-C, A CELL MEDIATED GENE THERAPY FOR
OSTEOARTHRITIS
B. Lee y, S. Totterman z, D. Gale z, A. Schreyer z, J. Cho y, T. Kim y,
Y. Park y, E. Jeong y. yKolon Life Sci., Inc., Gwacheon-si, Republic of Korea;
zQmetrics Tech., Rochester, NY, United States
Purpose: A randomized single-blind phase IIa trial was conducted in 28
patients with knee OA to determine both safety and efﬁcacy of TG-C.
TG-C is a cell mediated gene therapy that contains non-transduced
(hChonJ) and transduced (hChonJb#7) human allogeneic chondrocytes.
hChonJb#7 cells were transduced with TGF-b1 gene using retroviral
vector, while hChonJ cells were not modiﬁed. The hChonJb#7 cells were
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S400then irradiated with gamma-ray for preventing a replication of the cell
and went to a cell death.
Methods: MR images acquired at baseline (pre-treatment), as well as
6 and 12 months post-treatment, were evaluated by two experi-
enced musculoskeletal radiologists in a blinded fashion using a
modiﬁed WORMS (Whole Organ Magnetic Resonance Imaging Score)
method. After this scoring, the images were presented to the two
radiologists again, in time sequence, and radiological impressions
were generated for cartilage, and any signiﬁcant visible trends or
changes were identiﬁed. During the un-blinded radiological evalua-
tion a set of patients was noted to have improvements in the
cartilage.
Results: The following improvements were observed: full thickness
cartilage defect ﬁlling, generalized cartilage thickening in the defect
area, and improvement or resolution of cartilage blisters. One patient
showed several of these ﬁndings, and additionally showed considerable
bone regeneration (bone remodeling) and cartilage regeneration in the
trochlea, restoring the trochlea shape. Although these patients dem-
onstrated many areas of improvement, in some patients there was
evidence of progression of OA as well.
Conclusions: Based on these ﬁndings, there was an indication that in
certain cases this treatment induced cartilage regeneration.
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ASPIRIN IS ASSOCIATED WITH REDUCED CARTILAGE LOSS IN KNEE
OSTEOARTHRITIS: DATA FROM A COHORT STUDY
A. Wluka y, C. Ding z, Y. Wang y, G. Jones z, F. Cicuttini y. yMonash Univ.,
Melbourne, Australia; zMenzies Res. Inst. Tasmania, Hobart, Australia
Purpose: Inﬂammation and vascular disease are important in the
pathogenesis of osteoarthritis. Low dose aspirin has anti-inﬂammatory
and vasculoprotective effects. This study examined whether use of low
dose aspirin affects change in knee cartilage volume in osteoarthritis.
Methods: Participants from the Melbourne osteoarthritis cohort were
classiﬁed as users and non users of aspirin based aspirin use (<300 mg/
day) at baseline. Participant’s knees were imaged twice over 2 years.
Medial and lateral tibial cartilage volumes were measured and change
in cartilage volume was calculated.
Results: Twenty one (18%) of participants were aspirin users at baseline.
After adjustment for age, gender, body mass index and severity of
radiographic change, annual change in medial tibial cartilage volume
was43mm3 (95% conﬁdence intervals (CI)94, 5) in aspirin users and
101 mm3 (95% CI 124, 77) in non-users (P ¼ 0.048 for difference).
Similar results were seen for annual percentage loss (1.9% vs. 5.4%, p ¼
0.03). No difference was observed for lateral tibial cartilage change (p ¼
0.88)
Conclusions: Low dose aspirin use was associated with reduced medial
tibial cartilage loss over 2 years in people with knee osteoarthritis. This
data should be considered hypothesis generating and clinical trials are
required to conﬁrm efﬁcacy.
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DYSLIPIDEMIA IN PATIENTS WITH OSTEOARTHRITIS AND TYPE 2
DIABETES MELLITUS
M. Oliinyk. Kharkov Natl. Med. Univ., Kharkov, Ukraine
Purpose: To investigate inﬂuence of dyslipidemia to articular syndrome
and glycosylated hemoglobin (HbA1c) in patients with osteoarthritis
(OA) and type 2 diabetes mellitus (T2DM).
Methods:We examined 60 patients with knee OA and T2DM (28males,
age 58.7  4.7 years). Baseline characteristics of patients included his-
tory of OA (6.2  2.1 years), T2DM (7.3  2.7 years). All patients were
divided into 2 groups: 1st group – patients with OA, T2DM and con-
comitant dyslipidemia (n ¼ 31), 2nd group (n ¼ 29) – patients with OA,
T2DM and without concomitant dyslipidemia. The levels of total cho-
lesterol (TC), low-density lipoprotein cholesterol (LDL), very LDL (VLDL),
triglycerides (TG), high-density lipoprotein cholesterol (HDL), of HbA1c,
C-reactive protein were determined. All patients were made X-ray
examination of knees.
Results: Among the 1st group of patients the level of HbA1c was
signiﬁcantly correlated with TC level (r ¼ 0.58; p < 0.05), LDL (r ¼
0.48; p < 0.05), TG (r ¼ 0.42; p < 0.05), HDL (r ¼ 0.46; p < 0.05).
The study found that the level of C-reactive protein was sig-
niﬁcantly higher in patients with concomitant dyslipidemia (p <0.05). The degree of radiographic changes was signiﬁcantly more
increased in patients in the 1st group. We also noticed the severity
of radiographic changes were signiﬁcantly correlated with duration
of T2DM (r ¼ 0.41, p < 0.05).
Conclusions: Dyslipidemia can negatively affect the severity of articular
syndrome and HbA1c in patients with OA and T2DM.We recommend to
determine the level of lipid metabolism in patients with OA and T2DM
for prescribing adequate lipid-lowering therapy that can minimize the
risk of possible complications.Pain and Disability
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ASSESSMENT OF CHRONIC PAIN AFTER TOTAL KNEE REPLACEMENT:
DEVELOPMENT OF A CORE OUTCOME SET
V. Wylde y, J. Bruce z, F. MacKichan y, R. Gooberman-Hill y. yUniv. of
Bristol, Bristol, United Kingdom; zUniv. of Warwick, Warwick, United
Kingdom
Purpose: Total knee replacement (TKR) can be a successful operation
for providing pain relief, however approximately 20% of patients con-
tinue to experience chronic pain after TKR. The Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
includes pain in its recommendations for core outcomes to assess in
clinical trials of pain treatment. However, pain is multidimensional and
there are no recommendations about which aspects of pain should be
assessed. In this project, we aim to develop a core outcome set for the
assessment of chronic pain after TKR using a Delphi survey. This core
outcome set will represent the minimum pain information that should
be measured and reported in clinical trials focusing on chronic pain
after TKR.
Methods: This project is funded through a National Institute for Health
Research Programme Development Grant on the treatment and man-
agement of chronic pain after TKR (the STAR programme).
Phase I: identiﬁcation of pain features
A Delphi survey requires that a long-list of possible domains has been
developed, which adequately reﬂects previous research and the views
of patients and clinicians. A list of pain feature that can be assessed after
TKR has been developed through three studies:
1.) Systematic review of 1,164 articles which assessed pain at a mini-
mum of 3-months after TKR.
2.) Three focus groups with 14 health care professionals.
3.) Brief interviews with 50 patients experiencing chronic pain after
TKR.
Phase II: Delphi survey
A 3-round Delphi survey with patients and clinicians is being under-
taken to achieve consensus in the reduction of the long-list of pain
features to a core outcome set. In round 1, participants are asked to rate
the importance of assessing each pain feature from 1–9 (very important
to very unimportant). Those pain features given an importance rating of
7–9 by at least 70% of each of the two panels (patients and clinicians)
and rated as 1–3 by less than 15%, or given an important rating of 7–9 by
90% or more members of one panel, are retained and carried forward to
round 2. In round 2, participants are provided with group feedback and
asked to re-rate the pain features. In round 3, participants are asked to
rate their level of agreement that each pain feature should be included
in a core outcome set.
Results: Phase I: identiﬁcation of pain features
A long-list of 56 pain features was developed from the systematic
review, focus groups and brief interviews with patients. The features
identiﬁed focused on pain intensity, temporal aspects of pain, pain with
activities/movements, pain interference, recovery and pain after TKR,
emotional aspects of pain and use of pain medications.
Phase II: Delphi survey
123 participants have been recruited into the Delphi survey (80 patients
with chronic pain after TKR and 43 clinicians with relevant experience).
In round 1, participants rated the importance of the 56 pain features
identiﬁed in Phase I. Of these 56 pain features, 33 were retained and
carried forward to round 2. Rounds 2 and 3 of the Delphi survey are
currently ongoing and will be completed by January 2014. The core
outcome set will be ﬁnalised by March 2014 and ready for presentation
at the OARSI conference in April 2014.
